Plasma Protein Binding of Lidocaine and Warfarin in Insulin-Dependent and Non-Insulin-Dependent Diabetes Mellitus
- 14 Downloads
We examined the plasma protein binding of an acidic drug (warfarin bound to albumin) and a basic drug [lidocaine (lignocaine) bound to α1-acid glycoprotein] in 15 patients with insulin-dependent diabetes mellitus (IDDM) and 15 matched controls. We also examined protein binding of warfarin and lidocaine in 30 patients with non-insulin-dependent diabetes (NIDDM) and 25 controls. Compared with control, the binding of both warfarin (98.81 ± 0.02 vs 98.57 ± 0.03%, mean ± SEM) and of lidocaine (69 ± 2 vs 58 ± 2%) was significantly reduced in IDDM. This group had lower concentrations of both albumin and α1-acid glycoprotein (AAG), achieving statistical significance vs control for albumin only. In the patients with NIDDM, who had a similar level of glycosylated haemoglobin, while there was no significant difference in the binding of lidocaine there was a significant increase in warfarin binding compared with the control population (99.01 ± 0.03 vs 98.82 ± 0.04%). This study suggests that binding of both acidic and basic drugs is altered in both IDDM and NIDDM.
KeywordsWarfarin Lidocaine Plasma Protein Binding Drug Binding Basic Drug
Unable to display preview. Download preview PDF.
- Dengler TJ, Robertz-Vaupel GM, Dengler HJ. Endogenous ligands and structural changes inhibit binding to human serum albumin in chronic renal failure. European Journal of Clinical Pharmacology 36 (Suppl. 1): A65, 1989Google Scholar
- Kemp SF, Kearns GL, Turley CP. Altered Phenytoin binding in children with epilepsy. Clinical Pharmacology and Therapeutics 41: 170, 1987Google Scholar